Wendy’s blocks activist bid with poison pill plan

Wendy’s rejected a $1.4 billion acquisition proposal from an activist investor group and implemented a shareholder rights plan to shield the company from a hostile takeover. The Dublin, Ohio-based chain announced the decision on Thursday, stating that the bid failed to account for the long-term earnings potential of its current leadership strategy. The board of directors adopted the defensive measure, commonly known as a poison pill, to increase the cost of acquiring a controlling stake in the company.

The offer came from Nelson Peltz and partners, who hold 16.3% of Wendy’s shares. Peltz argued that the fast-food sector faces increasing challenges, including high beef prices, aging stores, and consumer pressure. He described his proposal as the best path forward for shareholders. A committee of independent directors unanimously voted to reject the offer, determining that it substantially undervalued the company. The shareholder rights plan allows existing shareholders, excluding the hostile bidder, to purchase discounted shares. This mechanism dilutes the bidder’s ownership stake and triggers automatically if a single entity or group controls 15% or more of the company’s stock.

Bob Wright, who assumed the CEO role in May, defended the company’s direction during a conference call with investors. Wright, the fourth CEO to lead the chain since 2024, previously served as president and CEO of Potbelly and held senior roles at Checkers and Domino’s Pizza. He expressed confidence that the company possesses the necessary strategy and resources to restore its potential. Wright noted that the turnaround plan, dubbed Dave’s Way, is already yielding positive results. The initiative focuses on improving food quality, enhancing marketing, and streamlining digital ordering and restaurant operations.

Wendy’s reported third-quarter revenue of $547 million for the July-September period, exceeding the $531 million forecast by analysts polled by FactSet. Same-store sales declined by 5.2%, a performance that also beat analyst expectations of a 6.4% drop. Shares rose less than 1% on Thursday following the announcement. The company operates 5,969 restaurants in the United States and 1,428 outlets in 38 countries, according to figures from the end of 2025.

The chain has worked to revitalize its portfolio by closing underperforming locations. Wendy’s shut down 240 restaurants in 2024 and plans to close up to 358 sites in 2026. In September, Meritage Hospitality Group, a major franchisee operating 314 locations across 15 states, filed for bankruptcy protection after the chain attempted to terminate its agreement. The company is currently testing menu changes, including thicker bacon, creamier Frosties, and whole-leaf lettuce. Management is also removing lower-volume menu items and making breakfast optional to reduce kitchen complexity.

Peltz served as chairman of the Wendy’s board for 17 years until 2024. His son, Bradley Peltz, remains on the board and operates as a franchisee. Trian Fund Management, Peltz’s firm, did not immediately respond to requests for comment on the rejection. The adoption of the one-year poison pill plan follows a similar move by Dine Brands, the parent company of Applebee’s and IHOP, which implemented a defensive measure last week to counter a takeover bid.

Wendy’s share of U.S. burger chain sales decreased from 11.5% in 2019 to 10.4% last year, according to market research firm Technomic. The broader industry has experienced a decline in customer traffic, with third-quarter foot traffic in the U.S. fast-food sector dropping by 2.6%, per Revenue Management Solutions. The chain, founded in 1969 by Dave Thomas, introduced the drive-thru window in 1970 and went public in 1976.